Dosing of unfractionated heparin in acute coronary syndromes

Pharmacotherapy

Volumn 24, Issue 12 I, 2004, Pages 1681-1691

  Badawi, Omar ^a   Oyen, Lance J ^b   Haines, Stuart T ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b ST MARY S HOSPITAL   (United States)

Author keywords

Acute coronary syndromes; Anticoagulation; Pharmacokinetics; Unfractionated heparin

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANISTREPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN; RECEPTOR BLOCKING AGENT; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ACUTE HEART INFARCTION; ANTICOAGULATION; BLEEDING; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DIABETES MELLITUS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BINDING; DRUG DOSE REDUCTION; DRUG HALF LIFE; HEART MUSCLE ISCHEMIA; HEPARINIZATION; HUMAN; OBESITY; PATHOPHYSIOLOGY; REVIEW; SMOKING HABIT; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM;

ACUTE DISEASE; BODY WEIGHT; CORONARY DISEASE; HEPARIN; HUMANS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 9644295686     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.17.1681.52349     Document Type: Review

References (50)

1. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on the management of patients with unstable angina). J Am Coll Cardiol 2002;40:1366-74.
2. Goodman SG, Cohen M, Bigonzi F, et al. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease. J Am Coll Cardiol 2000;36:693-8.
3. Klein W, Buchwald A, Hillis SE, et al. Comparison of low-molecular weight heparin with unfractionated heparin acutely and with placebo for six weeks in the management of unstable coronary-artery disease: Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997;96:61-8.
4. The SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004;292:45-54.
5. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94.
6. Diop D, Aghababian RV. Diagnosis and treatment of acute myocardial infarction: definition, classification, and pathophysiology of acute coronary ischemic syndromes. Emerg Med Clin North Am 2001;19:259-67.
7. Braunwald E, Califf RM, Cannon CP, et al. Redefining medical treatment in the management of unstable angina. Am J Med 2000;108:41-53.
8. Handin RI. Bleeding and thrombosis. In: Fauci AS, Braunwald E, Isselbacher KJ, et al, eds. Harrison's principles of internal medicine, 14th ed. New York: McGraw-Hill, 1998:339-45.
9. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: heparin. Circulation 1994;89:1449-68.
10. Bennet JS, Cassileth PA. Both sides of the hypercoagulable state. Hosp Pract (office ed) 1997;32:105-8, 111-12, 119-21.
11. DiSalvo TG, Fuster V, Israel DH, et al. Combination therapy in vaso-occlusive disease. In: Messerli FH, ed. Cardiovascular drug therapy, 2nd ed. Philadelphia: WB Saunders, 1996:101-18.
12. Lam J, Chesebro J, Steele PM, Dewanjee MK, Badimon L, Fuster V. Deep arterial injury during experimental angioplasty: relation to a positive indium-III platelet scintigram, quantitative platelet deposition and mural thrombosis. J Am Coll Cardiol 1986;8:1380-6.
13. Heras M, Chesebro J, Webster MWI. Hirudin, heparin, and placebo during deep arterial injury in the pig. Circulation 1990;82:1476-84.
14. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.
15. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-96.
16. Tolleson TR, O'Shea JC, Bittl JA, et al. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention. J Am Coll Cardiol 2003;41:386-93.
17. Anand SS, Yusuf S, Pogue J, Ginsberg JS, Hirsh J. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Circulation 2003;107:2884-8.
18. Granger CB, Hirsh J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 1996;93:870-8.
19. Gilchrist IC, Berkowitz SD, Thompson TD, Califf RM, Granger CB. Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Am Heart J 2002;144:73-80.
20. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram: a randomized controlled trial. Ann Intern Med 1993;119:874-81.
21. White RH, Zhou H, Woo L, Mungall D. Effect of weight, sex, age, clinical diagnosis, and thromboplastin reagent on steadystate intravenous heparin requirements. Arch Intern Med 1997;157:2468-72.
22. Kandrotas RJ. Heparin pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1992;22:359-74.
23. Verstraete M. Heparin. In: Messerli FH, ed. Cardiovascular drug therapy. Philadelphia: WB Saunders, 1996:1473-80.
24. Olsson P, Lagergren H, Ek S, et al. The elimination from plasma of intravenous heparin: An experimental study on dogs and humans. Acta Med Scand 1963;173:619-30.
25. Mungall D, Raskob G, Coleman R, Rosenbloom D, Ludden T, Hull R. Pharmacokinetics and dynamics of heparin in patients with proximal-vein thrombosis. J Clin Pharmacol 1989;29:896-900.
26. Bjornsson TO, Wolfram BS, Kitchell BB. Heparin kinetics determined by three assay methods. Clin Pharmacol Ther 1982;31:104-13.
27. De Swart CAM, Nijmeyer MB, Roelofs JMM, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. Blood 1982;60:1251-8.
28. Raskob GE, Hull RD, Pineo GF. Heparin, hirudin, and related agents. In: Beutler E, Lichtman MA, Coller BS, eds. William's hematology, 6th ed. New York: McGraw-Hill, 2001:1793-9.
29. Bussey HI. Problems with monitoring heparin anticoagulation. Pharmacotherapy 1999;19:2-5.
30. Smythe MA, Mattson JC, Koerber JM. The heparin anti-Xa therapeutic range: are we there yet? Chest 2002;121:303-4.
31. Trujillo TC, Nolan PE Jr, Quan RA, Slack MK, Ewy GA. Optimization of heparin therapy in patients with unstable angina or acute myocardial infarction using a multiple regression-derived dosing nomogram [abstr]. Pharmacotherapy 1996;16:492-3.
32. Flaker GC, Bartolozzi J, Davis V, McCabe C, Cannon CP. Use of a standardized heparin nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction. Arch Intern Med 1994;154:1492-6.
33. Lackie CL, Luzier AB, Donovan JA, Feras HI, Forrest A. Weight-based heparin dosing: clinical response and resource utilization. Clin Ther 1998;20:699-710.
34. Shalansky KF, FitzGerald M, Sunderji R, et al. Comparison of a weight-based heparin nomogram with traditional heparin dosing to achieve therapeutic anticoagulation. Pharmacotherapy 1996;16:1076-84.
35. Yee WP, Norton LL. Optimal weight base for a weight-based heparin dosing protocol. Am J Health-Syst Pharm 1998;552:159-62.
36. Spruill WJ, Wade WE, Huckaby WG, Leslie RB. Achievement of anticoagulation by using a weight-based heparin dosing protocol for obese and nonobese patients. Am J Health-Syst Pharm 2001;58:2143-6.
37. Zanke B, Shojania AM. Comparison of two aPTT methods of monitoring heparin therapy. Am J Clin Pathol 1990;93:684-9.
38. D'Angleo A, Seveso MP, D'Angelo SV, et al. Effect of clogdetection methods and reagents on activated partial thromboplastin time (aPTT). Am J Clin Pathol 1990;94:297-306.
39. Kitchen S. Problems in laboratory monitoring of heparin dosage. Br J Haematol 2000;111:397-406.
40. Heyns A, Berg DJ, Kleynhaus PHT, et al. Unsuitability of evacuated tubes for monitoring heparin therapy by activated partial thromboplastin time. Am J Clin Pathol 1981;34:63-8.
41. Sherman DS, Clarke SH, Lefkowitz JB, Valuck RJ, Lindenfeld J, Stringer KA. An institution-specific heparin titration nomogram: development, validation, and assessment of compliance. Pharmacotherapy 2001;21:1167-74.
42. Liepman CI, Koerber JM, Mattson JC, Westley SJ, Smythe MA. Comparing methods of establishing the aPTT therapeutic range of heparin. Ann Pharmacother 2003;37:794-8.
43. Becker RC, Cannon CP, Tracy RP, et al. Relationship between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q-wave myocardial infarction. Am Heart J 1996;131:421-33.
44. Paradiso-Hardy FL, Cheung B, Geerts WH. Evaluation of an intravenous heparin nomogram in a coronary care unit. Can J Cardiol 1996;12:802-8.
45. Rainville EC, Airoldi MR, Sheehey JM, Battle RW. A cardiology heparin dosing protocol. Hosp Pharm 1996;31:1596-602.
46. Hochman JS, Wali AU, Gavrila D, et al. A new regimen for heparin use in acute coronary syndromes. Am Heart J 1999;138:313-18.
47. Mungall D, Lord M, Cason S, Treadwell P, Williams D, Tedrick D. Developing and testing a system to improve the quality of heparin anticoagulation in patients with acute coronary syndromes. Am J Cardiol 1998;82:574-9.
48. Flaker GC, Bartolozzi J, Davis V, McCabe C, Cannon CP. Use of a standardized heparin nomogram to achieve therapeutic anticoagulation after thrombolytic therapy in myocardial infarction: TIMI 4 investigators: thrombolysis in myocardial infarction. Arch Intern Med 1994;154:1492-6.
49. Lee MS, Wali AU, Menon V, et al. The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. J Thromb Thrombolysis 2002;14:91-101.
50. OASIS-2 Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999;353:429-38.